Disitamab Vedotin
Gastroesophageal Junction Adenocarcinoma
Explore 110 assets in Gastroesophageal Junction Adenocarcinoma →Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
BeOne Medicines
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06585488CT.gov A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | — | Terminated | — | — | — |
NCT06157892CT.gov A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | — | Recruiting | — | — | — |
NCT05649163CT.gov Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy | — | Unknown | — | — | — |
NCT04276493CT.gov Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastroesophageal Junction Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Disitamab Vedotin (this asset) | BeOne Medicines | P2 | BB · 67 |
| Irinotecan | AstraZeneca | P3 | BBB |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P3 | BB |
| Pembrolizumab | Eikon Therapeutics | P3 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Levofolinic Acid | Merck Sharp & Dohme LLC | P3 | BB |
| Oxaliplatin | Alliance for Clinical Trials in Oncology | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Shenyang Sunshine Pharmaceutical Co., LTD. | P3 | BB |
+42 more in the Gastroesophageal Junction Adenocarcinoma cohort
Other indications for Disitamab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| HER2 Positive Breast Carcinoma | — | P4 | BB · 64 |
| Colorectal Cancer | — | P4 | B · 61 |
| Breast Cancer | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Disitamab Vedotin in Gastroesophageal Junction Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/disitamab-vedotin-gastroesophageal-junction-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →